Educational evidence summaries. No dosing, sourcing, or treatment instructions.
Evidence, safety and regulatory analysis of CJC-1295.
A claim-by-claim review separating measured GH and IGF-1 changes from unproven claims about fat loss, muscle growth, sleep, recovery and anti-aging.
Reviewed by Sports Integrity DeskAn evidence-led CJC-1295 and Ipamorelin Combination review focused on terminology audit, human-study limits, regulatory context and claim verification.
Reviewed by CJC Axis Editorial TeamA structured review of the landmark CJC-1295 healthy-adult trials, including endpoints, results, half-life and what the study cannot establish.
Reviewed by Endocrine Evidence DeskCompare two GHRH receptor agonists by molecular design, duration, human evidence, historical approval and current regulatory status.
Reviewed by Regulatory Review DeskA map of GHRH analogues and ghrelin-receptor secretagogues showing where CJC-1295, sermorelin, ipamorelin and GHRP-6 fit.
Reviewed by Sports Integrity DeskAn athlete-focused overview of CJC-1295, ipamorelin, sermorelin and GHRP-6 under the 2026 anti-doping framework.
Reviewed by Clinical Trial Review TeamAn evidence-led CJC-1295 DAC review focused on evidence checklist, human-study limits, regulatory context and claim verification.
Reviewed by CJC Axis Editorial TeamAn evidence-led CJC-1295 DAC review focused on research gaps map, human-study limits, regulatory context and claim verification.
Reviewed by Sports Integrity DeskAn evidence-led CJC-1295 DAC review focused on glucose and metabolic context, human-study limits, regulatory context and claim verification.
Reviewed by Regulatory Review Desk